GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. - Wikidata - awgldk - TriplyDB

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.

http://www.wikidata.org/entity/Q41984767

about

Incretin-Based Therapy for Prevention of Diabetic Vascular Complications New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies GLP-1 and cardioprotection: from bench to bedside Cardioprotective Signature of Short-Term Caloric Restriction Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms DPP4 deficiency preserved cardiac function in abdominal aortic banding rats Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study)Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.GIP and GLP-1, the two incretin hormones: Similarities and differences Epac is required for GLP-1R-mediated inhibition of oxidative stress and apoptosis in cardiomyocytes Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.Prognostic value of plasma DPP4 activity in ST-elevation myocardial infarction Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies Cardiovascular and hemodynamic effects of glucagon-like peptide-1.Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.DPP4 deficiency exerts protective effect against H2O2 induced oxidative stress in isolated cardiomyocytes.Exendin-4 improves cardiac function in mice overexpressing monocyte chemoattractant protein-1 in cardiomyocytes.Mitigation of autophagy ameliorates hepatocellular damage following ischemia-reperfusion injury in murine steatotic liver.Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies.Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney.Diabetes and cardiovascular disease: the potential benefit of incretin-based therapies GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways.PEGylated exendin-4, a modified GLP-1 analog exhibits more potent cardioprotection than its unmodified parent molecule on a dose to dose basis in a murine model of myocardial infarction.

P2860

Q26765470-F419A740-7559-416B-BB70-113C5EB843D6 Q26777654-665F1538-C80D-4063-B235-DCD659789FE3 Q26829634-99AE603D-261F-4CCF-81FE-C42809049F48 Q26866958-DCECAA65-B94A-4449-AE24-B722262E7017 Q27024984-C1F16EDF-7EDB-43B6-8A51-36F5CA84788E Q27303840-B8A00E5A-0B69-43E1-90AB-A9882722825A Q28067465-A6CB3D5F-D75F-431D-951B-F70CA6D97979 Q28070416-AF1965AC-6579-4811-B3CA-AF27C4AC3FE9 Q28079849-5D087C7E-94AD-4799-B4CC-38CE74CD077D Q28081569-1E27BB26-9B62-4204-A2D3-EA9FB2C85725 Q28081671-6D2D8C65-0F3F-49B8-86B9-04391F2CB2C7 Q28535415-1C684CE3-38AA-416B-8F6C-55C804B75BA7 Q28538591-EF8C364F-7133-4B5E-BC84-8877F50EE0FB Q28740948-9775D57B-608A-4D53-B472-92A3780CBD95 Q30437335-440CBA65-ED29-47B8-94C2-0EEAA7363CCB Q30580723-A8AE6096-16E6-4207-A663-95107D4A6A37 Q33486125-D416E763-7639-4ECF-808A-B5E48FF004A3 Q33521451-9270A884-47B4-4E84-8FAC-0A753300B91A Q33602360-4423AF02-8A03-462E-AB9F-E5645D6579E8 Q33603384-761C4C34-3382-4758-B9F9-0916AD726150 Q33609502-E94DAC07-704B-403D-88BE-791D5CF321C8 Q33631733-611EFE26-A2FD-4B27-AF11-5D500D4A17B9 Q33750640-04EA55DD-BF3F-4834-A888-0FD0169A013F Q33771334-C915C70B-BAA0-4EE0-BA0C-579014B6918C Q33785308-2B9A1BB5-10BA-4438-AFC4-68DC069310D6 Q33880174-7522DF50-97EE-4D69-BFA5-0BD885BECEA7 Q33939256-B6A0AE4E-C7D1-4F51-BFF0-97E6FD632C86 Q33949425-D0E7F6F8-C345-4AD8-879F-944D5C48FA39 Q33993725-4A9F51C1-ED96-4B14-9EE1-3CD917A2D3DA Q34041974-FCF2D2BB-6FDC-44AD-B52C-109FB49BB5F9 Q34062829-83506FAA-A762-4A84-ABBA-119407909AAF Q34336097-81802B26-785E-4B36-A5E2-CA579C001BAB Q34566411-CE8BE642-BC1D-4D36-B76B-9F596530E51B Q34603269-FD46EB81-EFCC-4E0E-BF00-68F02687EE35 Q34627493-872B4880-CE18-47D1-9B2C-8B6D31D8724E Q34640125-7C83EC62-40C8-4C4C-8D3E-F360055ACECC Q34690495-90E195FF-8987-494C-8BA4-5AD15F948595 Q34716791-2A806FB3-70BA-403A-B3C7-F5D7F0D2D3D4 Q34727731-9E812937-401E-4533-9DB7-E1D9101E88F7 Q34785887-11946D37-FF25-4221-ADE9-7DE6D441282C

P2860

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.

http://www.wikidata.org/entity/Q41984767

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

GLP-1R agonist liraglutide act ...... myocardial infarction in mice.

@en

type

label

GLP-1R agonist liraglutide act ...... myocardial infarction in mice.

@en

prefLabel

GLP-1R agonist liraglutide act ...... myocardial infarction in mice.

@en

P1433

Q41984767-4D4696F6-9F87-4A5F-B80F-2405C47F4BD4

P1476

Q41984767-39B3CF4A-364A-49A5-A24E-9FCCEB648CD2

P2093

Q41984767-0F73FC65-E161-4C5B-8D7C-2595DECFF95E

Q41984767-10D6B60C-DC3F-4759-8DB5-22B3DAE5AC8E

Q41984767-6C121F50-ADC4-4AB1-A70D-47628F9768E0

Q41984767-79B2D9E3-6B83-41EA-BE18-8A655D473949

Q41984767-7B17D786-DE2C-4642-98D1-672BFFA860BF

Q41984767-A12E5AF0-B81B-432D-B638-E9EB3A5DD85F

Q41984767-ACF357E5-F5FB-4F56-B90F-D5E3291F0B7C

Q41984767-CBB8BD04-7893-4D72-B0AF-E71A4DDAD428

Q41984767-EE73D6E6-FE32-42FD-9C2A-DC5C806BC379

P2860

Q41984767-010218B1-2051-4A88-83D9-C029175FB7EF

Q41984767-01E81B7B-C5AA-4A84-B48A-22E17E142E98

Q41984767-0CFD9F5E-8302-4F80-990D-87AF7F435546

Q41984767-1E9638F8-9F7A-4AC4-B5CA-C9DC7BF733A2

Q41984767-1F6D80C2-83B9-447A-94A7-9F63AEF5F187

Q41984767-2597C5DF-8A8D-4689-8B9B-933A0451AACF

Q41984767-2E1ADC7C-4839-4E03-921A-61986735D287

Q41984767-3328EF8B-43B7-467F-BF4D-DC801C584834

Q41984767-33412F8C-7BED-4525-8FE2-69BDB792EBFD

Q41984767-3B2AD05C-EC54-47A5-8D8F-FAAB983418EA

P304

Q41984767-BFD541F0-A2AE-4ABD-9DA3-6A1F09E91BF3

P31

Q41984767-5D81017F-F064-401F-A42D-ED4EAD82980E

P356

Q41984767-D1BF8534-AB1E-4E7C-B606-665713A7C70E

P407

Q41984767-273D3A40-D193-4E16-8B7C-D4FC366158BF

P433

Q41984767-A892B16A-7990-4ABD-A824-A40D31E14EFC

P478

Q41984767-F1B2422B-D3FA-48B5-94F5-DF322B65EBF1

P50

Q41984767-69CD10ED-13A0-4E28-818D-DC735A43F122

P577

Q41984767-515CE42C-FE99-45F1-AE58-597E753A85EF

P5875

Q41984767-91F2922D-5630-494D-94F7-C02C49BB0BE8

P698

Q41984767-52ECF254-2339-47F9-B7CD-46FFCA15AF7D

P921

Q41984767-A65EB5DE-A7A1-43EA-8528-CA65BC9AEC26

P932

Q41984767-8ABEF81E-B791-4E0E-9BFF-860F290F6839

P356

P1433

P1476

GLP-1R agonist liraglutide act ...... myocardial infarction in mice.

@en

P2093

Al-Muktafi Sadi

http://www.w3.org/2001/XMLSchema#string

Ali M Riazi

http://www.w3.org/2001/XMLSchema#string

Kiwon Ban

http://www.w3.org/2001/XMLSchema#string

Laurie L Baggio

http://www.w3.org/2001/XMLSchema#string

M Abdul Momen

http://www.w3.org/2001/XMLSchema#string

Mansoor Husain

http://www.w3.org/2001/XMLSchema#string

Mohammad Hossein Noyan-Ashraf

http://www.w3.org/2001/XMLSchema#string

R Mark Henkelman

http://www.w3.org/2001/XMLSchema#string

Yu-Qing Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

Regulation of cardiac hypertrophy by intracellular signalling pathways

Simultaneous evaluation of infarct size and cardiac function in intact mice by contrast-enhanced cardiac magnetic resonance imaging reveals contractile dysfunction in noninfarcted regions early after myocardial infarction.

The preconditioning phenomenon: A tool for the scientist or a clinical reality?

Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore

Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart.

Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction.

P304

975-983

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB08-1193

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

Daniel J. Drucker

P577

2009-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46872367

http://www.w3.org/2001/XMLSchema#string

P698

19151200

http://www.w3.org/2001/XMLSchema#string

P921

P932

2661586

http://www.w3.org/2001/XMLSchema#string